Stock Detail
FOREST LABORATORIES INC CLASS A
Drug Manufacturers Other
FRX @ Yahoo Finance | FRX Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $29.76 | $30.11 | $-0.49 | -1.62% | 0.00 | $30.25 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $30.06 | $29.75 | 3.62M | 7.95B | 3.01M | 7.36 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 30.23 | 29.99 | 29.87 | 29.63 | 29.51 |
Stock Profile
Forest Laboratories, Inc. engages in the development, manufacture, and sale of both branded and generic forms of ethical drug products, as well as nonprescription pharmaceutical products sold over-the-counter. The company's products include Lexapro, Celexa, Namenda, Tiazac, Benicar, Benicar HCT, Milnacipran, CCR1, Lercanidipine, Campral, and Combunox. The Lexapro and Celexa are used for the initial and maintenance treatment of depressive disorders, and for generalized anxiety disorders. The Namenda, an N-methyl-D-aspartate-receptor antagonist, is used for the treatment of moderate to severe Alzheimer's disease. The Tiazac, Benicar, Benicar HCT, and Lercanidipine are used for hypertension. The Milnacipran is in Phase III development for the treatment of fibromyalgia syndrome. The CCR1 is a chemokine receptor involved in the inflammation process. Campral is used for the maintenance of abstinence from alcohol in patients with alcohol dependence. Combunox, an opioid and NSAID combination, is used for the short-term management of pain. It also has various products under development, which include RGH-188 in Phase I clinical trials, an atypical antipsychotic for the treatment of schizophrenia, bipolar mania, and other psychiatric conditions; phase I completed GRC 3886, a novel, orally available Phosphodiesterase-IV inhibitor in development for chronic obstructive pulmonary disorder and asthma; and Desmoteplase, a novel plasminogen activator, or blood clot-dissolving agent. The company markets its products directly and though independent distributors worldwide to physicians, pharmacies, hospitals, managed care, and other healthcare organizations. The company has strategic alliances with H. Lundbeck A/S; Merz Pharma GmbH; Sankyo Pharma; Merck Sante s.a.s.; Gedeon Richter Ltd.; Glenmark Pharmaceuticals; PAION GmbH; ChemoCentryx, Inc.; Cypress Bioscience, Inc.; and Recordati, S.p.A. Forest Laboratories was organized in 1956 and is based in New York City.